Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.
2.

Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.

Burkitt K, Ljungman M.

Cancer Lett. 2007 Aug 8;253(1):131-7. Epub 2007 Feb 26.

PMID:
17321670
3.

RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.

Dai CH, Li J, Chen P, Jiang HG, Wu M, Chen YC.

J Biomed Sci. 2015 Sep 18;22:77. doi: 10.1186/s12929-015-0185-4.

4.
5.

Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.

Jacquemont C, Simon JA, D'Andrea AD, Taniguchi T.

Mol Cancer. 2012 Apr 26;11:26. doi: 10.1186/1476-4598-11-26.

6.

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.

Nakashima S, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Asaoka T, Hama N, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M.

Cancer Sci. 2015 May;106(5):584-91. doi: 10.1111/cas.12652. Epub 2015 Apr 22.

7.

Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor.

Rego MA, Harney JA, Mauro M, Shen M, Howlett NG.

Oncogene. 2012 Jan 19;31(3):366-75. doi: 10.1038/onc.2011.237. Epub 2011 Jun 20.

8.

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.

Kachnic LA, Li L, Fournier L, Willers H.

Cancer Lett. 2010 Jun 1;292(1):73-9. doi: 10.1016/j.canlet.2009.11.009. Epub 2010 Jan 19.

PMID:
20034732
9.

The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.

Martens-de Kemp SR, Brink A, van der Meulen IH, de Menezes RX, Te Beest DE, Leemans CR, van Beusechem VW, Braakhuis BJ, Brakenhoff RH.

Mol Cancer Ther. 2017 Mar;16(3):540-550. doi: 10.1158/1535-7163.MCT-16-0457. Epub 2016 Dec 15.

PMID:
27980104
10.

Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.

Chen P, Li J, Jiang HG, Lan T, Chen YC.

Tumour Biol. 2015 May;36(5):3591-9. doi: 10.1007/s13277-014-2996-4. Epub 2014 Dec 27.

PMID:
25542235
11.

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.

Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS.

Cancer Res. 2009 Dec 15;69(24):9367-75. doi: 10.1158/0008-5472.CAN-09-2616.

12.

Detection of impaired homologous recombination repair in NSCLC cells and tissues.

Birkelbach M, Ferraiolo N, Gheorghiu L, Pfäffle HN, Daly B, Ebright MI, Spencer C, O'Hara C, Whetstine JR, Benes CH, Sequist LV, Zou L, Dahm-Daphi J, Kachnic LA, Willers H.

J Thorac Oncol. 2013 Mar;8(3):279-86. doi: 10.1097/JTO.0b013e31827ecf83.

13.

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.

Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD.

Mol Cancer Ther. 2006 Apr;5(4):952-61.

14.

Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer.

Park JW, Pitot HC, Strati K, Spardy N, Duensing S, Grompe M, Lambert PF.

Cancer Res. 2010 Dec 1;70(23):9959-68. doi: 10.1158/0008-5472.CAN-10-1291. Epub 2010 Oct 8.

15.
16.
17.

Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway.

Peremartí J, Ramos F, Marcos R, Hernández A.

Toxicol Sci. 2014 Nov;142(1):93-104. doi: 10.1093/toxsci/kfu159. Epub 2014 Aug 4.

PMID:
25092648
18.

Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.

Lombardi AJ, Hoskins EE, Foglesong GD, Wikenheiser-Brokamp KA, Wiesmüller L, Hanenberg H, Andreassen PR, Jacobs AJ, Olson SB, Keeble WW, Hays LE, Wells SI.

Clin Cancer Res. 2015 Apr 15;21(8):1962-72. doi: 10.1158/1078-0432.CCR-14-2616. Epub 2015 Jan 21.

19.

Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.

Ferrer M, de Winter JP, Mastenbroek DC, Curiel DT, Gerritsen WR, Giaccone G, Kruyt FA.

Cancer Gene Ther. 2004 Aug;11(8):539-46.

PMID:
15192709
20.

Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.

Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN.

Mol Cancer Res. 2009 Aug;7(8):1304-9. doi: 10.1158/1541-7786.MCR-09-0149. Epub 2009 Aug 11.

Supplemental Content

Support Center